recombinant fowlpoxvirus expressing hiv gag-pol antigens
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2002 (NCT00332930)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- recombinant fowlpoxvirus expressing hiv gag-pol antigens
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00332930 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2002 | Prescient Therapeutics, Ltd., University of New South Wales |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Prescient Therapeutics, Ltd. | For profit | 1 | 0 | 1 | 2002 |
| University of New South Wales | Academic/Hospital | 1 | 1 | 1 | 2002 |
2 organizations
Page 1 / 1